By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Drug 'does not decrease delirium duration'

The cholinesterase inhibiting drug rivastigmine (Exelon) does not decrease the duration of delirium in critically ill patients and could increase mortality, warn Dutch researchers.

They randomised 104 patients diagnosed with delirium to receive an increasing twice daily dose of rivastigmine or placebo, as an adjunct to usual care based on haloperidol. 

The trial was halted early because mortality in the rivastigmine group was higher than in the placebo group - 12 patients died compared with 4 controls.

Median duration of delirium was 5 days in the rivastigmine group, compared with 3 days in the placebo group.

The authors said: “We do not recommend treatment of delirium with rivastigmine for patients in intensive care.”

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!